Optic Neuritis

Neurologic Clinics

Volumn 28, Issue 3, 2010, Pages 573-580

  Clark, David ^a   Kebede, Workayehu ^a   Eggenberger, Eric ^a  

^a East Lansing   (United States)

Author keywords

Demyelination; Glatiramer acetate; Interferon; Multiple sclerosis; Optic neuritis

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; STEROID; ANTIINFLAMMATORY AGENT;

CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; HUMAN; INCIDENCE; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME; COMPLICATION; FRONTAL LOBE; MULTIPLE SCLEROSIS; OPTIC NERVE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OPTIC NERVE; OPTIC NEURITIS; PREDNISONE;

EID: 77954739019     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.03.001     Document Type: Review

References (16)

1. The clinical profile of acute optic neuritis: experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1991, 109:1673-1678.
2. Rodriguez M., Siva A., Cross S.A., et al. Optic Neuritis, a population-based study in Olmsted County, Minnesota. Neurology 1995, 45:244-250.
3. Swartz N.G., Beck R.W., Savino P.J., et al. Pain in anterior ischemic optic neuropathy. J Neuroophthalmol 1995, 15:9-10.
4. Rolak L.A., Beck R.W., Paty D.W., et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996, 46:368-372.
5. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997, 49:1404-1413.
6. Optic Neuritis Study Group High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003, 121:944-949.
7. Optic Neuritis Study Group Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008, 65(6):727-732.
8. Costello F., Hodge W., Pan Y., et al. Retinal nerve fiber layer and future risk of multiple sclerosis. Can J Neurol Sci 2008, 35:482-487.
9. Costello F., Coupland S., Hodge W., et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006, 59:963-969.
10. Naismith R.T., Tutlam N.T., Xu J., et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009, 72:1077-1082.
11. Beck R.W., Cleary P.A., Anderson M.M., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992, 326:581-588.
12. Beck R.W., Cleary P.A., Trobe J.D., et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993, 329:1764-1769.
13. CHAMPS Study Group Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001, 132(4):463-471.
14. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. (CHAMPS Study Group). N Engl J Med 2000, 343:898-904.
15. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
16. Comi G., Martinelli V., Godegher M., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blinded, placebo-controlled trial. Lancet 2009, 374:1503-1511.